Keymed Biosciences Inc. will convene its board of directors on 19 August 2026 to review and approve the interim financial statements for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend, if any.
The meeting was announced on 7 August 2026. Keymed Biosciences’ board is led by Chairman Dr. Bo Chen and comprises three executive directors, three non-executive directors and three independent non-executive directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments